GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
Go back to GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)| (NASDAQ: NRXP) | Delayed: 3.32 -0.07 (2.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.39 | 52 Week High | $ | |||
| Open | $3.38 | 52 Week Low | $ | |||
| Day High | $3.42 | P/E | N/A | |||
| Day Low | $3.31 | EPS | $ | |||
| Volume | 946,350 | |||||
